Description of Research Expertise:
My research and clinical interests focus on improving outcomes in patients with lymphomas. I am interested in the use of novel agents and cellular therapies. I also have been involved in research activities using molecular imaging to predict response to therapy. During my fellowship, I published work that helped to define the role of PET scans in patients undergoing autologous stem cell transplant (ASCT) for relapsed lymphoma. It showed that residual activity on pre-ASCT PET scan is associated with poor outcomes after ASCT. I later designed the first clinical trial based on these findings using lenalidomide maintenance after ASCT for patients with relapsed lymphomas who had residual PET positive disease prior ASCT. The phase I portion of the trial has successfully completed and currently phase II continues to actively enroll patients. My other active investigator initiated trial is using a combination of a novel antibody based agent brentuximab with traditional chemotherapy for patients with CD30+ B-cell lymphomas. It is now being opened at two other institutions and I am serving as multi-site PI. I also actively participate in trials using cellular therapies (CART19) in patients with non-Hodgkin lymphomas. In the future, I would like to concentrate mainly on Hodgkin lymphoma since I am fascinated by the immunology of this disease and there is a great need to develop less toxic therapies for this lymphoma subtype affecting mostly young adults. I am working on establishing a comprehensive program for patients with Hodgkin lymphoma at the Abramson Cancer Center at the University of Pennsylvania. I am also the principal investigator on the first trial using cellular therapy with CART19 cells in Hodgkin lymphoma. I am hoping to expand this novel approach for Hodgkin lymphoma patients with relapsed/refractory disease and further develop immune based therapies in this setting.
Stephen J. Schuster, M.D., Jakub Svoboda, M.D., Elise A. Chong, M.D., Sunita D. Nasta, M.D., Anthony R. Mato, M.D., Özlem Anak, M.D., Jennifer L. Brogdon, Ph.D., Iulian Pruteanu-Malinici, Ph.D., Vijay Bhoj, M.D., Ph.D., Daniel Landsburg, M.D., Mariusz Wasik, M.D., Bruce L. Levine, Ph.D., Simon F. Lacey, Ph.D., Jan J. Melenhorst, Ph.D., David L. Porter, M.D., and Carl H. June, M.D.: Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas New England Journal of Medicine 377 : 2545-2554,2017.
Jakub Svoboda, Susan R Rheingold, Saar I Gill, Stephan A Grupp, Simon F Lacey, J Joseph Melenhorst, Irina Kulikovskaya, Brandon Loudon, Naseem Kerr, Katherine T Marcucci, Kim-Marie Shea, Aliza Schmidt, Lester Lledo, Amy Marshall, Anthony R Mato, Sunita Dwivedy Nasta, Daniel J Landsburg, Matthew R Youngman, Bruce L Levine, David L Porter, Carl H June, Stephen J Schuster: Pilot Study of Non-Viral, RNA-Redirected Autologous Anti-CD19 Chimeric Antigen Receptor Modified T-Cells in Patients with Refractory/Relapsed Hodgkin Lymphoma (HL) Blood 130 : 653-653,2017.
Jakub Svoboda, Daniel J Landsburg, Sunita Dwivedy Nasta, Stefan Klaus Barta, Nadia Khan, Henry C Fung, Carlyn Rose Tan, Joanne Filicko-O'Hara, Sameh Gaballa, Lauren Elizabeth Strelec, Sarah J Nagle, Steven M Bair, Sheryl Mitnick, Terease S Waite, Rachel Lynn Sargent, Agata M Bogusz, Ziver Sahin, Anthony R Mato, Stephen J Schuster: Brentuximab Vedotin with R-CHP Chemotherapy As Frontline Treatment for Patients with CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, and Grey Zone Lymphomas: Results of a Phase I/II Multisite Trial Blood 130 (Suppl 1): 191-191,2017.
Nirav N Shah, Aniko Szabo, Scott F Huntington, Narendranath Epperla, Nishitha Reddy, Siddhartha Ganguly, Julie Vose, Cynthia Obiozor, Fahad Faruqi, Alexandra E Kovach, Luciano J Costa, Ana C Xaiver, Ryan Okal, Abraham S Kanate, Nilanjan Ghosh, Mohamed A Kharfan‐Dabaja, Lauren Strelec, Mehdi Hamadani, Timothy S Fenske, Oscar Calzada, Jonathon B Cohen, Julio Chavez, Jakub Svoboda: R‐CHOP versus dose‐adjusted R‐EPOCH in frontline management of primary mediastinal B‐cell lymphoma: a multi‐centre analysis British Journal of Haematology : 2017.
Ruan, J., Martin, P., Shah, B., Schuster, S.J., Smith, S.M., Furman, R.R., Christos, P., Rodriguez, A., Svoboda, J., Lewis, J., Katz, O., Coleman, M., and Leonard, J.P.: Lenalidomide Plus Rituximab as Initial Treatment for Mantle Cell
New England Journal of Medicine 373 (19): 1835-44,2015.
Huntington Scott F, Svoboda Jakub, Doshi Jalpa A: Cost-Effectiveness Analysis of Routine Surveillance Imaging of Patients With Diffuse Large B-Cell Lymphoma in First Remission. Journal of Clinical Oncology 33 (13): 1467-74,2015.
SM Bair, L Strelec, SJ Nagle, SD Nasta, DJ Landsburg, AR Mato, AW Loren, SJ Schuster, EA Stadtmauer, J Svoboda: Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis American Journal of Hematology : 2017.
Anthony R. Mato, Chadi Nabhan, Paul M. Barr, Chaitra S. Ujjani, Brian T. Hill, Nicole Lamanna, Alan P. Skarbnik, Christina Howlett, Jeffrey J. Pu, Alison R. Sehgal, Lauren E. Strelec, Alexandra Vandegrift, Danielle M. Fitzpatrick, Clive S. Zent, Tatyana Feldman, Andre Goy, David F. Claxton, Spencer Henick Bachow, Gurbakhash Kaur, Jakub Svoboda, Sunita Dwivedy Nasta, David Porter, Daniel J. Landsburg, Stephen J. Schuster, Bruce D. Cheson, Pavel Kiselev and Andrew M. Evens: Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience Blood : 2016.
AR Mato, BT Hill, N Lamanna, PM Barr, CS Ujjani, DM Brander, C Howlett, AP Skarbnik, BD Cheson, CS Zent, JJ Pu, P Kiselev, K Foon, J Lenhart, S Henick Bachow, AM Winter, A-L Cruz, DF Claxton, A Goy, C Daniel, K Isaac, KH Kennard, C Timlin, M Fanning, L Gashonia, M Yacur, J Svoboda, SJ Schuster, C Nabhan: Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients Annals of Oncology 28 (5): 1050-1056,2017.
Nagle, SJ, Woo, K, Schuster, SJ, Nasta, SD, Stadtmauer, E, Mick, R, Svoboda, J: Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era American Journal of Hematology 88 (10): 890-894,2013.